Literature DB >> 26961666

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?

Vittorio Fusco1, Alberto Bedogni2, Alfredo Addeo3, Giuseppina Campisi4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26961666     DOI： 10.1007/s00520-016-3147-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  25 in total

1.  Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement.

Authors:  Brian G M Durie
Journal:  Mayo Clin Proc       Date:  2007-04       Impact factor: 7.616

2.  Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?

Authors:  Luis Junquera; Lorena Gallego
Journal:  J Oral Maxillofac Surg       Date:  2008-07       Impact factor: 1.895

3.  American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition.

Authors:  Giuseppe Colella; Giuseppina Campisi; Vittorio Fusco
Journal:  J Oral Maxillofac Surg       Date:  2009-12       Impact factor: 1.895

4.  Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.

Authors:  Vittorio Fusco; Claudia Galassi; Alfredo Berruti; Libero Ciuffreda; Cinzia Ortega; Giovannino Ciccone; Alberto Angeli; Oscar Bertetto
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

5.  Comments on "diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus".

Authors:  Sven Otto; Robert E Marx; Matthias Tröltzsch; Oliver Ristow; Thomas Ziebart; Bilal Al-Nawas; Knut A Groetz; Michael Ehrenfeld; Valeria Mercadante; Stephen Porter; Alberto Bedogni; Giuseppina Campisi; Vittorio Fusco; Ezher Dayisoylu; Riham Fliefel; Bente Brokstad Herlofson; Christoph Pautke; Tae-Geon Kwon; Stefano Fedele
Journal:  J Bone Miner Res       Date:  2015-06       Impact factor: 6.741

Review 6.  Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

Authors:  Martha Q Lacy; Angela Dispenzieri; Morie A Gertz; Philip R Greipp; Kimberly L Gollbach; Suzanne R Hayman; Shaji Kumar; John A Lust; S Vincent Rajkumar; Stephen J Russell; Thomas E Witzig; Steven R Zeldenrust; David Dingli; P Lief Bergsagel; Rafael Fonseca; Craig B Reeder; A Keith Stewart; Vivek Roy; Robert J Dalton; Alan B Carr; Deepak Kademani; Eugene E Keller; Christopher F Viozzi; Robert A Kyle
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

7.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authors:  James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

Review 8.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

Authors:  M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976

9.  Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

Authors:  C I Ripamonti; M Maniezzo; T Campa; E Fagnoni; C Brunelli; G Saibene; C Bareggi; L Ascani; E Cislaghi
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

10.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976
View more
  9 in total

1.  Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points.

Authors:  Maura Rossi; Alessio Gambino; Marco Cabras; Manuela Alessio; Vittorio Fusco
Journal:  Support Care Cancer       Date:  2021-02-25       Impact factor: 3.603

2.  Response to letter to the Editors-Safety of long-term denosumab therapy.

Authors:  Alison T Stopeck; Douglas J Warner
Journal:  Support Care Cancer       Date:  2016-11-24       Impact factor: 3.603

3.  Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases.

Authors:  Francesco Erovigni; Alessio Gambino; Marco Cabras; Antonella Fasciolo; Silvio Diego Bianchi; Elisa Bellini; Vittorio Fusco
Journal:  Dent J (Basel)       Date:  2016-10-29

4.  Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition.

Authors:  Mario Migliario; Giovanni Mergoni; Paolo Vescovi; Iolanda De Martino; Manuela Alessio; Luca Benzi; Filippo Renò; Vittorio Fusco
Journal:  Dent J (Basel)       Date:  2017-03-16

5.  Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures.

Authors:  Gioacchino Catania; Federico Monaco; Giulia Limberti; Manuela Alessio; Iolanda De Martino; Cecilia Barile; Antonella Fasciolo; Anna Baraldi; Marco Ladetto; Vittorio Fusco
Journal:  Dent J (Basel)       Date:  2016-12-01

6.  Conservative non-surgical management in medication related osteonecrosis of the jaw: A retrospective study.

Authors:  Massimo Albanese; Francesca Zotti; Giorgia Capocasale; Stefano Bonetti; Fabio Lonardi; Pier Francesco Nocini
Journal:  Clin Exp Dent Res       Date:  2020-07-02

7.  Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?

Authors:  Giacomo Oteri; Giuseppina Campisi; Vera Panzarella; Ilaria Morreale; Riccardo Nucera; Olga Di Fede; Antonio Picone; Antonia Marcianò
Journal:  Biomed Res Int       Date:  2018-05-29       Impact factor: 3.411

8.  Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology.

Authors:  Vittorio Fusco; Giuseppina Campisi; Paul de Boissieu; Federico Monaco; Anna Baraldi; Gianmauro Numico; Alberto Bedogni
Journal:  Dent J (Basel)       Date:  2018-09-01

Review 9.  The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.

Authors:  Olga Di Fede; Vera Panzarella; Rodolfo Mauceri; Vittorio Fusco; Alberto Bedogni; Lorenzo Lo Muzio; Giuseppina Campisi
Journal:  Biomed Res Int       Date:  2018-09-16       Impact factor: 3.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.